Patent-filing research conducted by law firm Withers & Rogers suggests that CAR T-cell therapy capability has reached a pivotal point on route to market, and first-line use of these promising treatments for various forms of cancer is nearing, although it remains unclear how long it will take.
The first patents related to CAR T-cell therapy were filed in 2010, and the innovation curve, based on the volume of global patent filings, has gone from zero to 12,452 in just 12 years to the end of 2021, which is the last complete year of patent filing data.
However, global patent filing data for 2020 and 2021—the last two years of complete data - shows that the innovation curve is now levelling off, suggesting that a critical mass of patent applications may now have been reached, according to the findings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze